What question did this study set out to answer?

Evaluate the diagnostic performance of two commercial serological assays for strongyloidiasis in Chagas disease patients.

June 14, 2026PathogensOpen Access

Assessment of Two Commercial Serological Assays for the Diagnosis and Post-Treatment Follow-Up of Strongyloidiasis in a Cohort of Patients with Chagas Disease

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional evaluation reveals effective serological assays for diagnosing strongyloidiasis in Chagas disease patients, indicating their utility.

Evaluate the diagnostic performance of two commercial serological assays for strongyloidiasis in Chagas disease patients.
Cross-sectional evaluation of 55 patients with treated Chagas disease in a Tropical Medicine Unit in Spain.
Patients were screened using two ELISA assays for Strongyloides stercoralis and assessed for eosinophils.
Treatment response was evaluated one year post-ivermectin treatment.
37 patients (67.3%) met the criteria for strongyloidiasis.
Concordance between assays was substantial (κ = 0.80).
Treatment response rates were 83.3% with DRG and 73.3% with Euroimmun, with significant declines in eosinophil counts (p < 0.001).

Gil-Gallardo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional evaluation reveals effective serological assays for diagnosing strongyloidiasis in Chagas disease patients, indicating their utility.